Head, Clinical Pharmacology & Early Clinical Development
Takeda
Dr. Zhaoyang (Megan) Li, PhD, is currently Head, Clinical Pharmacology & Early Clinical Development in Plasma-Derived Therapy Business Unit at Takeda. Megan holds a PhD in Pharmaceutics from The Ohio State University, Columbus, Ohio, US, and a master’s degree as well as a bachelor’s degree in Chemistry from Beijing University, China. Prior to Takeda, Megan spent 11 years at Biogen and 9 years at Sanofi. Her experience in drug development includes a wide range of treatment modalities, encompassing protein therapeutics, oligonucleotides, and small molecule drugs, in a wide range of therapeutic areas.
Megan has a proven track record in leading the global clinical pharmacology programs and product-specific strategies for early and late-stage development programs, including critical contributions to the development and approvals of a few marketed drugs in Neurology, Immunology, Cardiovascular and Rare Disease therapeutical areas. Megan has been a member of ASCPT since 2000.
Disclosure information not submitted.
Wednesday, March 16, 2022
5:30 PM – 6:00 PM ET
.png)